Literature DB >> 12379652

Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.

Xiao-Jian Yao1, Julie Lemay, Nicole Rougeau, Martin Clément, Steve Kurtz, Pierre Belhumeur, Eric A Cohen.   

Abstract

Human immunodeficiency virus 1 (HIV-1) encodes a gene product, Vpr, that facilitates the nuclear uptake of the viral pre-integration complex in non-dividing cells and causes infected cells to arrest in the G(2) phase of the cell cycle. Vpr was also shown to cause mitochondrial dysfunction in human cells and budding yeasts, an effect that was proposed to lead to growth arrest and cell killing in budding yeasts and apoptosis in human cells. In this study, we used a genetic selection in Saccharomyces cerevisiae to identify hexameric peptides that suppress the growth arrest phenotype mediated by Vpr. Fifteen selected glutathione S-transferase (GST)-fused peptides were found to overcome to different extents Vpr-mediated growth arrest. Amino acid analysis of the inhibitory peptide sequences revealed the conservation of a di-tryptophan (diW) motif. DiW-containing GST-peptides interacted with Vpr in GST pull-down assays, and their level of interaction correlated with their ability to overcome Vpr-mediated growth arrest. Importantly, Vpr-binding GST-peptides were also found to alleviate Vpr-mediated apoptosis and G(2) arrest in HIV-1-producing CD4(+) T cell lines. Furthermore, they co-localized with Vpr and interfered with its nuclear translocation. Overall, this study defines a class of diW-containing peptides that inhibit HIV-1 Vpr biological activities most likely by interacting with Vpr and interfering with critical protein interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379652     DOI: 10.1074/jbc.M207982200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  A potentially general method for the in vivo selection of inhibitory peptides targeted at a specific protein using yeast.

Authors:  Jacques H Daniel
Journal:  Curr Genet       Date:  2008-05-14       Impact factor: 3.886

Review 2.  HIV-1 viral protein R (Vpr) and its interactions with host cell.

Authors:  Ge Li; Michael Bukrinsky; Richard Y Zhao
Journal:  Curr HIV Res       Date:  2009-03       Impact factor: 1.581

Review 3.  The Vpr protein from HIV-1: distinct roles along the viral life cycle.

Authors:  Erwann Le Rouzic; Serge Benichou
Journal:  Retrovirology       Date:  2005-02-22       Impact factor: 4.602

Review 4.  The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.

Authors:  María Eugenia González
Journal:  Int J Mol Sci       Date:  2017-01-10       Impact factor: 5.923

5.  The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.

Authors:  Tracy L Hartman; Robert W Buckheit
Journal:  Mol Biol Int       Date:  2012-07-10

6.  HIPdb: a database of experimentally validated HIV inhibiting peptides.

Authors:  Abid Qureshi; Nishant Thakur; Manoj Kumar
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

7.  Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.

Authors:  Zaikun Xu; Yingfeng Zheng; Zhujun Ao; Martin Clement; Andrew J Mouland; Ganjam V Kalpana; Pierre Belhumeur; Eric A Cohen; Xiaojian Yao
Journal:  Retrovirology       Date:  2008-11-14       Impact factor: 4.602

8.  Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae.

Authors:  Xiao-Jian Yao; Nicole Rougeau; Ghislaine Duisit; Julie Lemay; Eric A Cohen
Journal:  Retrovirology       Date:  2004-08-16       Impact factor: 4.602

Review 9.  HIV Associated Neurocognitive Disorders.

Authors:  Li Zhou; Nitin K Saksena
Journal:  Infect Dis Rep       Date:  2013-06-06

Review 10.  Development of peptide inhibitors of HIV transmission.

Authors:  Siyu Shi; Peter K Nguyen; Henry J Cabral; Ramon Diez-Barroso; Paul J Derry; Satoko M Kanahara; Vivek A Kumar
Journal:  Bioact Mater       Date:  2016-09-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.